The FDA has approved a new form of the opioid oxycodone, which was developed by New York-based Pfizer (NYSE: [[ticker:PFE]]) and Palatine, IL-based Acura Pharmaceuticals (NASDAQ: [[ticker:ACUR]]), according to a press release. The product, branded as Oxeta, applies technology developed by Acura that is designed to discourage common methods of tampering associated with opioid abuse.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
